Literature DB >> 10861582

Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease.

R Geiger1, R M Berger, J Hess, A J Bogers, H S Sharma, W J Mooi.   

Abstract

Congenital heart disease (CHD) leading to increased pulmonary blood pressure and flow is an important cause of pulmonary plexogenic arteriopathy (PPA). This type of arteriopathy tends to progress to an irreversible stage, hallmarked histologically by the emergence of a number of characteristic lesions, which include concentric laminar intimal proliferation and fibrosis, and plexiform lesions. The pathogenesis of these lesions, which connote a very poor prognosis, is not well understood. Since endothelial cell proliferation has been demonstrated in these lesions, it was hypothesized that vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, might play a role in their pathogenesis. Thirty-nine patients with various types of CHD, who underwent cardiac catheterization and subsequent cardiac surgery, were studied prospectively. On the basis of a detailed assessment of the type of cardiac defect, the haemodynamic abnormalities, and the histopathological features evident from open lung biopsies, taken in all instances, patients were histologically grouped into cases with moderate PPA (n=18), advanced PPA (n=7), pulmonary congestive vasculopathy (PCV, n=5), and controls lacking pulmonary hypertension or increased pulmonary blood flow (n=4). Five patients were excluded from analysis because of inadequate sample size or quality. The presence of VEGF was assessed immunohistochemically using standard procedures and was correlated with haemodynamic and histological data. Immunoreactive VEGF was detected in pulmonary arterial smooth muscle cells and endothelial cells in 13 out of 34 cases and was more frequent and more pronounced in patients with the histological lesions of advanced PPA than in those with moderate PPA (p<0.01). VEGF positivity was particularly prominent in the lesions characteristic of advanced PPA. No difference in VEGF expression was observed between controls, PVC, and moderate PPA cases. Measured haemodynamic parameters did not differ significantly between VEGF-positive and VEGF-negative cases. We conclude that VEGF may play a role in the angioproliferative changes of advanced PPA. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861582     DOI: 10.1002/(SICI)1096-9896(200006)191:2<202::AID-PATH608>3.0.CO;2-D

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

Review 2.  Targeting non-malignant disorders with tyrosine kinase inhibitors.

Authors:  Friedrich Grimminger; Ralph T Schermuly; Hossein A Ghofrani
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

3.  Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.

Authors:  Jing Tian; Sohrab Fratz; Yali Hou; Qing Lu; Agnes Görlach; John Hess; Christian Schreiber; Sanjeev A Datar; Peter Oishi; John Nechtman; Robert Podolsky; Jin-Xiong She; Jeffrey R Fineman; Stephen M Black
Journal:  Physiol Genomics       Date:  2010-10-26       Impact factor: 3.107

4.  Pulmonary tumor thrombotic microangiopathy showing aggressive course after transurethral resection of urinary bladder: an autopsy case report.

Authors:  Hiroshi Hirano; Hirotoshi Ichibori; Tomohiko Kizaki; Takuya Matsumoto; Zyunichi Ohka; Takeshige Mori; Masanobu Okamoto; Daisuke Ogasawara; Kohei Kamemura; Ryohei Yoshikawa; Takeshi Itagaki; Yuichi Matsuda; Hiroshi Sano
Journal:  Med Mol Morphol       Date:  2012-12-07       Impact factor: 2.309

5.  Pulmonary vascular changes in piglets with increased pulmonary blood flow and pressure.

Authors:  Matthias Gorenflo; Esther Herpel; Michael V Ullmann; Karoline Röhlig; Sueha Demirakca; Homa Klimpel; Siegfried Hagl; Martha Maria Gebhard; Philipp A Schnabel
Journal:  Virchows Arch       Date:  2007-04-21       Impact factor: 4.064

Review 6.  mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.

Authors:  Elena A Goncharova
Journal:  FASEB J       Date:  2013-01-25       Impact factor: 5.191

Review 7.  Reactive oxygen species in pulmonary vascular remodeling.

Authors:  Saurabh Aggarwal; Christine M Gross; Shruti Sharma; Jeffrey R Fineman; Stephen M Black
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

Review 8.  Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

9.  S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy.

Authors:  Steven Greenway; Robert Jan van Suylen; Gideon Du Marchie Sarvaas; Edwin Kwan; Noona Ambartsumian; Eugene Lukanidin; Marlene Rabinovitch
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 10.  Signal transduction in the development of pulmonary arterial hypertension.

Authors:  Simon Malenfant; Anne-Sophie Neyron; Roxane Paulin; François Potus; Jolyane Meloche; Steeve Provencher; Sébastien Bonnet
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.